For the Inventor, By the Inventor

Enter assignee name

Culver City, CA, United States of America

Nantcell, Inc.

USPTO Granted Patents = 42

CIPO Patents = 1

EPO Patents = 4

Trademarks = 2

Forward Citations = 28

Loading Chart...

Loading Chart...

30 inventors (with patents filed for the assignee):

Patrick Soon-Shiong (25 out of 443 patents)

Kayvan R Niazi (20 out of 90 patents)

Shahrooz Rabizadeh (14 out of 82 patents)

4. Hans G Klingemann (5 out of 39 patents)

5. Stephen Charles Benz (5 out of 53 patents)

6. John H Lee (4 out of 12 patents)

7. Laurent H Boissel (4 out of 28 patents)

8. Bing Song (3 out of 77 patents)

9. Jeffrey Safrit (3 out of 5 patents)

10. Barry J Simon (3 out of 16 patents)

11. Mustafa Jaber (3 out of 21 patents)

12. Christopher W Szeto (3 out of 12 patents)

13. Nicholas James Witchey (3 out of 143 patents)

14. Liudmila A Beziaeva (3 out of 11 patents)

15. Hing C Wong (2 out of 104 patents)

Core Competencies:

T-cell Memory

Immunosuppressed Treatment

Neoepitope Vectors

HIV Treatment Compositions

COVID-19 Therapeutics

Deep Learning Models

Bacillus Calmette-Guerin

Patient-Specific Therapeutics

Electroporation Techniques

Tumor Evaluation

Personalized Vaccines

Immune Therapy

42 patents: Sort by Forward Citations

1. 12491201 - Maximizing T-cell memory and compositions and methods therefor (2025-12-09),

2. 12427184 - Treatment of immunosuppressed subjects (2025-09-30),

3. 12311018 - Targeted neoepitope vectors and methods therefor (2025-05-27),

4. 12303552 - Treatment of immunosuppressed subjects (2025-05-20),

5. 12303477 - HIV treatment compositions and methods (2025-05-20),

6. 12297247 - Fusion molecules of CTLA4 and IL-15 (2025-05-13),

7. 12285481 - Methods for the treatment of COVID-19 comprising administering replication-defective adenoviruses encoding the SARS-CoV-2 spike glycoprotein and modified nucleocapsid protein (2025-04-29),

8. 12285480 - Method of inducing immunity against SARS-CoV-2 using spike and nucleocapsid-ETSD immunogens delivered by RNA and replication-defective adenoviruses (2025-04-29),

9. 12224066 - Deep learning models for region of interest determination (2025-02-11),

10. 12224064 - Deep learning models for tumor evaluation (2025-02-11),

11. 12168048 - Bacillus Calmette-Guerin (BCG) and antigen presenting cells for treatment of bladder cancer (2024-12-17),

12. 12156901 - Treatment of immunosuppressed subjects (2024-12-03),

13. 12112838 - Production and delivery tracking and sample verification of patient-specific therapeutics (2024-10-08),

14. 12050802 - Object storage and access management systems and methods (2024-07-30),

15. 12016911 - Bacillus Calmette-Guerin (BCG) and antigen presenting cells for treatment of bladder cancer (2024-06-25),

NantCell is a biotechnology company dedicated to revolutionizing cancer treatment through the development of innovative immunotherapies. With a focus on personalized therapies, NantCell aims to provide effective and targeted treatments for a wide range of cancer types. Leveraging cutting-edge technologies and a deep understanding of the immune system, NantCell is committed to improving patient outcomes and making significant advancements in the fight against cancer.

This text is generated by artificial intelligence and may not be accurate.

Company Badge

USPTO Data Jan 1 1976 - Dec 16 2025

42 Patents

#11 in Culver City, CA

#1,882 in California

#7,985 in US

#15,857 in the World

Culver City, CA, United States of America

Nantcell, Inc.

Forward Citations = 28

30 inventors:

Patrick Soon-Shiong (25 out of 443 patents)

Kayvan R Niazi (20 out of 90 patents)

Shahrooz Rabizadeh (14 out of 82 patents)

4. Hans G Klingemann (5 out of 39 patents)

5. Stephen Charles Benz (5 out of 53 patents)

Please report any incorrect information to support@idiyas.com

Loading…